CREB3L1 is a Metastasis Suppressor That Represses Expression of Genes Regulating Metastasis, Invasion, and Angiogenesis
Overview
Affiliations
The unfolded protein response (UPR) is activated in response to hypoxia-induced stress such as in the tumor microenvironment. This study examined the role of CREB3L1 (cyclic AMP [cAMP]-responsive element-binding protein 3-like protein 1), a member of the UPR, in breast cancer development and metastasis. Initial experiments identified the loss of CREB3L1 expression in metastatic breast cancer cell lines compared to low-metastasis or nonmetastatic cell lines. When metastatic cells were transfected with CREB3L1, they demonstrated reduced invasion and migration in vitro, as well as a significantly decreased ability to survive under nonadherent or hypoxic conditions. Interestingly, in an in vivo rat mammary tumor model, not only did CREB3L1-expressing cells fail to form metastases compared to CREB3L1 null cells but regression of the primary tumors was seen in 70% of the animals as a result of impaired angiogenesis. Microarray and chromatin immunoprecipitation with microarray technology (ChIP on Chip) analyses identified changes in the expression of many genes involved in cancer development and metastasis, including a decrease in those involved in angiogenesis. These data suggest that CREB3L1 plays an important role in suppressing tumorigenesis and that loss of expression is required for the development of a metastatic phenotype.
Reproducible processing of TCGA regulatory networks.
Fanfani V, Shutta K, Mandros P, Fischer J, Saha E, Micheletti S bioRxiv. 2024; .
PMID: 39574772 PMC: 11580957. DOI: 10.1101/2024.11.05.622163.
The Regulatory Network of CREB3L1 and Its Roles in Physiological and Pathological Conditions.
Zhao Y, Yu Z, Song Y, Fan L, Lei T, He Y Int J Med Sci. 2024; 21(1):123-136.
PMID: 38164349 PMC: 10750332. DOI: 10.7150/ijms.90189.
Molecular targets and therapeutic strategies for triple-negative breast cancer.
Bhat Y, Thrishna M, Banerjee S Mol Biol Rep. 2023; 50(12):10535-10577.
PMID: 37924450 DOI: 10.1007/s11033-023-08868-6.
Wu C, Yu S, Wang Y, Gao Y, Xie X, Zhang J Front Pharmacol. 2023; 14:1212420.
PMID: 37719863 PMC: 10501863. DOI: 10.3389/fphar.2023.1212420.
Ponomaryova A, Schegoleva A, Gervas P, Pancova O, Gerashchenko T, Zarubin A Mol Biol Rep. 2023; 50(9):7941-7947.
PMID: 37480511 DOI: 10.1007/s11033-023-08571-6.